Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster

[1]  G. Lozanski,et al.  Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants , 2022, The New England journal of medicine.

[2]  J. Dye,et al.  LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants , 2022, Cell Reports.

[3]  S. Shen,et al.  Different pathogenesis of SARS-CoV-2 Omicron variant in wild-type laboratory mice and hamsters , 2022, Signal Transduction and Targeted Therapy.

[4]  H. Wei,et al.  ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants , 2022, Signal Transduction and Targeted Therapy.

[5]  Liyuan Liu,et al.  Antibody evasion properties of SARS-CoV-2 Omicron sublineages , 2022, Nature.

[6]  D. Fremont,et al.  An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies , 2022, Nature Medicine.

[7]  G. Gao,et al.  Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2 , 2022, Cell.

[8]  S. Madhi,et al.  SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses , 2022, Cell.

[9]  J. Dye,et al.  LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants , 2021, bioRxiv.

[10]  D. Fremont,et al.  An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies , 2021, Research square.

[11]  P. Maes,et al.  Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.

[12]  Fei Shao,et al.  Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.

[13]  Liyuan Liu,et al.  Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 , 2021, Nature.

[14]  A. Telenti,et al.  Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift , 2021, Nature.

[15]  O. Tsang,et al.  Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients , 2021, medRxiv.

[16]  Chenglin Deng,et al.  Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice , 2021, Signal Transduction and Targeted Therapy.

[17]  Philip L. Tzou,et al.  The biological and clinical significance of emerging SARS-CoV-2 variants , 2021, Nature Reviews Genetics.

[18]  K. Lundstrom.  Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer , 2021, Vaccines.

[19]  F. Rey,et al.  Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.

[20]  D. Ho,et al.  Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization , 2021, Cell Host & Microbe.

[21]  D. Ho,et al.  Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.

[22]  Vineet D. Menachery,et al.  The variant gambit: COVID-19’s next move , 2021, Cell Host & Microbe.

[23]  R. Yan,et al.  ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker , 2020, bioRxiv.

[24]  D. Weissman,et al.  Messenger RNA-Based Vaccines Against Infectious Diseases. , 2020, Current topics in microbiology and immunology.

[25]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[26]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[27]  James E. Crowe,et al.  A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection , 2019, Science Immunology.

[28]  T. Daemen,et al.  An alphavirus-based therapeutic cancer vaccine: from design to clinical trial , 2018, Cancer Immunology, Immunotherapy.

[29]  Jonathan L. Kirschman,et al.  Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection , 2018, Nature Communications.

[30]  T. Schlake,et al.  mRNA mediates passive vaccination against infectious agents, toxins, and tumors , 2017, EMBO molecular medicine.

[31]  D. Weissman,et al.  Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge , 2017, Nature Communications.

[32]  K. Ljungberg,et al.  Self-replicating alphavirus RNA vaccines , 2015, Expert review of vaccines.

[33]  T. Dubensky,et al.  An Alphavirus Replicon Particle Chimera Derived from Venezuelan Equine Encephalitis and Sindbis Viruses Is a Potent Gene-Based Vaccine Delivery Vector , 2003, Journal of Virology.

[34]  T. Dubensky,et al.  Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.